Abstract
Some rare disease treatments come from drug repurposing. The biopharma industry focuses on commercial rare disease drug repurposing, and disease-specific non-profits and governments focus on philanthropic rare disease drug repurposing. In the future, it is likely that both groups will increase their use of drug repurposing as a means of developing treatments for rare diseases, but for different reasons.